Skip to main navigation Skip to search Skip to main content

The selective cyclooxygenase-2 inhibitor rofecoxib may improve the treatment of chronic idiopathic urticaria

  • W. H. Boehncke*
  • , R. J. Ludwig
  • , T. M. Zollner
  • , F. Ochsendorf
  • , R. Kaufmann
  • , B. F. Gibbs
  • *Corresponding author for this work
  • Johann Wolfgang Goethe-University
Original languageEnglish
JournalBritish Journal of Dermatology
Volume148
Issue number3
Pages (from-to)604-606
Number of pages3
ISSN0007-0963
DOIs
Publication statusPublished - 01.03.2003

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Cite this